Subglottis cancer

Summary

Subglottis cancer (MONDO:0001293) is a cancer. A subtype of subglottis neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	subglottis cancer
Mondo ID	MONDO:0001293
DOID	DOID:11472
ICD-10-CM	C32.2
NCIT	C3546
SNOMED CT	363430007
UMLS	C0153485
MedGen	57562
GARD	0027571
Anatomy (UBERON)	UBERON:0036068
Is cancer (heuristic)	yes

Also known as: cancer of subglottis · malignant neoplasm of subglottis · malignant neoplasm of the subglottis · malignant subglottic neoplasm · malignant subglottic tumor · malignant subglottic tumour · malignant subglottis neoplasm · malignant subglottis tumor · malignant subglottis tumour · malignant tumor of subglottis · malignant tumor of the subglottis · malignant tumour of subglottis · malignant tumour of the subglottis · subglottis cancer

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › upper respiratory tract disorder › laryngeal disorder › laryngeal neoplasm › subglottis neoplasm › subglottis cancer

Related subtypes (1): benign neoplasm of subglottis

Subtypes (1): subglottis carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.